Brain Natriuretic Peptides (BNP)

Normal Plasma Peptide/Protein Levels

Protocol	Assay Protocol (PDF)
Sample Preparation	Blood collection Plasma extraction Tissue extraction CSF extraction
Catalog #	EK-011-17
Standard Size	96 wells
Sensitivity	Minimum Detectable Concentration = 0.3 ng/ml
Range	0-100 ng/ml
Linear Range	0.3-4.73 ng/ml
Cross Reactivity	Peptide   %Cross-reactivity  BNP-45 (Rat)  100  BNP-32(Rat)  100  BNP-45 (Mouse)  11.3  BNP-32 (Porcine)  0  BNP-26 (Porcine)  0  BNP-32 (Human)  0  BNP-32 (Canine)  0  ANP (Rat)  0  a-ANP (1-28) (Human, Canine)  0  Endothelin-1  0  Angiotensin II (Human)  0
Sequence	Ser - Gln - Asp - Ser - Ala - Phe - Arg - Ile - Gln - Glu - Arg - Leu - Arg - Asn - Ser - Lys - Met - Ala - His - Ser - Ser - Ser - Cys - Phe - Gly - Gln - Lys - Ile - Asp - Arg - Ile - Gly - Ala - Val - Ser - Arg - Leu - Gly - Cys - Asp - Gly - Leu - Arg - Leu - Phe Disulfide Bridge:Cys23 - Cys39
Image

Please click here or click the reference tab on the top to see more articles that use this product.

Links to publications that use this kit:

Deres L, Bartha E, Palfi A, et al. PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.
PLoS ONE. 2014;9(7):e102148.

Szymanski MK, Buikema JH, Van veldhuisen DJ, et al. Increased cardiovascular risk in rats with primary renal dysfunction; mediating role for vascular endothelial function.
Basic Res Cardiol. 2012;107(2):242.

Angelini A, Castellani C, Ravara B, et al. Stem-cell therapy in an experimental model of pulmonary hypertension and right heart failure: role of paracrine and neurohormonal milieu in the remodeling process.
J Heart Lung Transplant. 2011;30(11):1281-93.

Tada Y, Kagota S, Matsumoto M, et al. Characterization of cardiac size and function in SHRSP.Z-Lepr(fa)/IzmDmcr rats, a new animal model of metabolic syndrome.
Biol Pharm Bull. 2010;33(12):1971-6.

Van esch JH, Moltzer E, Van veghel R, et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
J Hypertens. 2010;28(10):2145-55.

Gutte H, Oxbøl J, Kristoffersen US, Mortensen J, Kjaer A. Gene expression of ANP, BNP and ET-1 in the heart of rats during pulmonary embolism.
PLoS ONE. 2010;5(6):e11111. 

Bartha E, Solti I, Kereskai L, et al. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
Cardiovasc Res. 2009;83(3):501-10.

Ferdinal F, Suyatna FD, Wanandi SI, Sadikin M. Expression of B-type natriuretic peptide-45 (BNP-45) gene in the ventricular myocardial induced by systemic chronic hypoxia.
Acta Med Indones. 2009;41(3):136-43.

Bartha et al. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
J Cardiovasc Pharmacol. 2008 Sep;52(3):253-61.

Palfi et al. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
J Mol Cell Cardiol. 2006 Jul;41(1):149-59.

Szabó C. Cardioprotective effects of poly(ADP-ribose) polymerase inhibition.
Pharmacol Res. 2005;52(1):34-43.

Smithline - Acad Emergency Med Vol. 9 - Number 5 481 2002